title: Cardiovascular chemotherapy: anticoagulants.
abstract: Anticoagulant therapy has changed dramatically during the past two years. Low molecular weight heparin has substantially replaced unfractionated heparin as the parenteral anticoagulant of choice. The use of warfarin has substantially increased, especially for prevention of stroke in the setting of atrial fibrillation. It has become clear that warfarin cannot be administered effectively in an unmonitored fixed-dose fashion. The parenteral direct thrombin inhibitor desirudin was shown to be efficacious in the prevention of deep vein thrombosis in man. Small thrombin and factor Xa inhibitors with in vivo oral anticoagulant activity have been identified.
authors.affiliation: Merck Research Laboratories, West Point, PA 19486, USA. Jules_Shafer@Merck.com
authors.forename: J A
authors.initials: JA
authors.lastname: Shafer
mesh_terms: D000925:Anticoagulants / Q000737:chemistry / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D015195:Drug Design; D065427:Factor Xa Inhibitors; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000517:prevention & control; D013917:Thrombin / Q000037:antagonists & inhibitors; D013923:Thromboembolism / Q000188:drug therapy; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D013917:Thrombin